Use of Medroxyprogesterone Acetate as a Contraceptive in conjunction with Early Postpartum Rubella Vaccination

Sharp, David S.; Macdonald, Helen
November 1973
British Medical Journal;11/24/1973, Vol. 4 Issue 5890, p443
Academic Journal
No abstract available.


Related Articles

  • Effect of depot medroxyprogesterone acetate on vaginal bleeding in the puerperium. Murphy, H.M. // British Medical Journal;12/1/1979, Vol. 2 Issue 6202, p1400 

    Examines the effect of depot medroxyprogesterone acetate (DMPA) associated to vaginal bleeding in puerperium. Intervention of DMPA postpartum; Effectiveness of DMPA as a contraceptive; Availability of the method to patients use.

  • Long-acting Contraception for Pain Control in Patients with Endometriosis. Edelman, Alison // OB/GYN Clinical Alert;Apr2009, Vol. 25 Issue 12, p91 

    After 6 months of use, both depot medroxyprogesterone acetate and the contraceptive implant (Implanon®) significantly decreased pain associated with endometriosis.

  • Bone density in women receiving depot medroxprogesterone acetate for contraception. Cundy, Tim; Evans, Margaret; Roberts, Helen; Wattie, Diana; Ames, Ruth; Reid, Ian R. // BMJ: British Medical Journal (International Edition);7/6/91, Vol. 303 Issue 6793, p13 

    Examines the use of injectable contraceptive depot medroxyprogesterone acetate in women. Implications of injectable contraceptives; Assessment of bone mineral density by energy x-ray absorptiometry; Effects of contraceptives to bone density in women.

  • Depo-Provera: An injectable contraceptive. Earl, Daniel Thad; David, Daniel J. // American Family Physician;3/1/1994, Vol. 49 Issue 4, p891 

    Discusses the use of medroxyprogesterone acetate (Depo-Provera) as an injectable contraceptive. Indications and advantages; Dosage and administration; Contraindications; Side effects; Case studies on the use of the drug. INSET: Depo-provera--an injectable contraceptive..

  • Research eyes DMPA, cancer risks/benefits.  // Contraceptive Technology Update;Jul2012, Vol. 33 Issue 7, p80 

    The article discusses research reported in the article "Choosing a Contraceptive: Efficacy, Safety, and Personal Considerations" by J. Trussell and K. A. Guthrie, which found that there is an increased cancer risk associated with using the injectable contraceptive depot medroxyprogesterone acetate.

  • New contraceptive eligibility checklists for provision of combined oral contraceptives and... Stang, Amanda; Schwingl, Pamela // Bulletin of the World Health Organization;2000, Vol. 78 Issue 8, p1015 

    Examines the contraceptive eligibility checklists for provision of combined oral contraceptives and depot-medroxyprogesterone acetate in community programs. Evaluation of checklists used for eligibility criteria; Checklist development, review and revision; Field-testing.

  • New research emerges on DMPA fracture risks.  // Contraceptive Technology Update;May2013, Vol. 34 Issue 5, p53 

    The article describes a study which found a small increase in the risk of bone fractures in women who used the contraceptive injection depot medroxyprogesterone acetate (DMPA), but researchers did not attribute the risk to the drug itself.

  • Does Injectable Contraceptive Cause Bone Loss in Women? Walling, Anne D. // American Family Physician;5/15/1999, Vol. 59 Issue 10, p2890 

    Presents an excerpt from the study `Bone Mineral Density in Women Using Depot Medroxyprogesterone Acetate for Contraception,' by D. Scholes et al which appeared in the February 1999 issue of `Obstetrics & Gynecology.'

  • Does DMPA use increase fracture risk in women?  // Contraceptive Technology Update;Nov2010, Vol. 31 Issue 11, p125 

    The article discusses research which was conducted on a population of women between the ages of 20-44 and which suggests that use of the contraceptive injection depot medroxyprogesterone acetate (DMPA) Is associated with an increased risk of fractures.

  • Injectable use and bone density. Althaus, Frances // International Family Planning Perspectives;Jun99, Vol. 25 Issue 2, p59 

    Discusses the abstract entitled `Bone density among long-term users of medroxyprogesterone acetate as a contraceptive,' by L.C. Paiva, A.M. Pinto-Neto et al published in the 1998 issue of `Contraception'. Decrease of bone mass as a result of long-term use of injection contraceptive...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics